Embryo's Genetic and Chromosomal Quality Clinical Trial
The aim of this study is to performed a randomized controlled trial to evaluate the rate of
genetic and chromosomal abnormalities in embryos obtained from GnRH-agonist long and
GnRH-antagonist ovarian stimulation protocols.
Patients will be prospectively randomized in two groups: the first undergoing controlled
ovarian stimulation in GnRH-agonist long protocol and the second following GnRH-antagonist
ovarian stimulation regimen.
The end-points of the study include the number of genetically and chromosomally abnormal
embryos, the pregnancy, the implantation and the healthy baby birth rate.
The patients included in PGS program were selected on the base of advanced maternal age,
repeated pregnancy lost and implantation failure whereas the patients who were know to carry
sex-linked or monogenic disorders were considered for PGD strategy.
The uterine abnormalities, endometriosis and endocrinal diseases were considered to be the
exclusion factors.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening